Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 2, 2015, Pages 232-240

  Spoto, Belinda ^a   Mattace Raso, Francesco ^b   Sijbrands, Eric ^b   Leonardis, Daniela ^a   Testa, Alessandra ^a   Pisano, Anna ^a   Pizzini, Patrizia ^a   Cutrupi, Sebastiano ^a   Parlongo, Rosa M ^a   D’Arrigo, Graziella ^a   Tripepi, Giovanni ^a   Mallamaci, Francesca ^a   Zoccali, Carmine ^a  

^a CNR   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DYSPNEA; ELECTROCARDIOGRAPHY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERLEUKIN 6 GENE; LIPID BLOOD LEVEL; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; THORAX RADIOGRAPHY; BLOOD; CARDIOVASCULAR DISEASES; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; INCIDENCE; ITALY; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; PHENOTYPE; PROGNOSIS; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; STATISTICAL MODEL; TIME FACTOR; UPREGULATION;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INCIDENCE; INTERLEUKIN-6; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84923769173     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07000714     Document Type: Article

References (49)

1. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 340: 115–126, 1999.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973–979, 1997.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836–843, 2000.
4. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: In- flammatorymarkers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599–2610, 2004.
5. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V: Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5: e78, 2008.
6. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E; Cholesterol and Recurrent Events (CARE) Investigators: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98: 839–844, 1998.
7. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105: 1135–1143, 2002.
8. Davey Smith G, Hemani G: Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 23[R1]: R89–R98, 2014.
9. Hingorani AD, Casas JP; Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium: The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379: 1214–1224, 2012.
10. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19: 2364–2367, 1999.
11. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, Bavendiek U, von Felden J, Divchev D, Kempf T, Wollert KC, Seegert D, Rose-John S, Tietge UJ, Schieffer B, Grote K: Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler ThrombVasc Biol 32: 281–290, 2012.
12. Zoccali C: Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective. Kidney Int 70: 26–33, 2006.
13. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M: IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int 67: 1216– 1233, 2005.
14. Zoccali C, Mallamaci F, Tripepi G: Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 19[Suppl 5]: V67–V72, 2004.
15. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767–1772, 2000.
16. Pecoits-Filho R, Bárány P, Lindholm B, Heimbürger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17: 1684–1688, 2002.
17. Zoccali C, Tripepi G, Mallamaci F: Dissecting inflammation in ESRD: Do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 17[Suppl 3]: S169–S173, 2006.
18. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: Serum albumin, Creactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47: 139–148, 2006.
19. Meuwese CL, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, Qureshi AR, Barany P, Heimburger O, Lindholm B, Krediet RT, Boeschoten EW, Carrero JJ: Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-a are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 26: 1313–1318, 2011.
20. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS: Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 45: 324–333, 2005.
21. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox): Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77: 550–556, 2010.
22. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE, Powell JT: Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 103: 2260–2265, 2001.
23. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE: Interleukin-6 gene -174g.c and -572g.c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21: 1458–1463, 2001.
24. Jerrard-Dunne P, Sitzer M, Risley P, Steckel DA, Buehler A, von Kegler S, Markus HS; Carotid Atherosclerosis Progression Study: Interleukin-6 promoter polymorphism modulates the effects of heavy alcohol consumption on early carotid artery atherosclerosis: the Carotid Atherosclerosis Progression Study (CAPS). Stroke 34: 402–407, 2003.
25. Wypasek E, Undas A, Sniezek-Maciejewska M, Kapelak B, Plicner D, Stepien E, Sadowski J: The increased plasma C-reactive protein and interleukin-6 levels in patients undergoing coronary artery bypass grafting surgery are associated with the interleukin-6-174G. C gene polymorphism. Ann Clin Biochem 47: 343–349, 2010.
26. Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, Smith MW, Coresh J: IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 17: 863–870, 2006.
27. Gillerot G, Goffin E, Michel C, Evenepoel P, Biesen WV, Tintillier M, Stenvinkel P, Heimbürger O, Lindholm B, Nordfors L, Robert A, Devuyst O: Genetic and clinical factors influence the baseline permeability of the peritonealmembrane. Kidney Int 67: 2477–2487, 2005.
28. Jenny NS, Tracy RP, Ogg MS, Luong A, Kuller LH, Arnold AM, Sharrett AR, Humphries SE: In the elderly, interleukin-6 plasma levels and the -174G.C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 22: 2066–2071, 2002.
29. Di Gaetano C, Voglino F, Guarrera S, Fiorito G, Rosa F, Di Blasio AM, Manzini P, Dianzani I, Betti M, Cusi D, Frau F, Barlassina C, Mirabelli D, Magnani C, Glorioso N, Bonassi S, Piazza A, MatulloG: An overview of the genetic structure within the Italian population from genome-wide data. PLoS ONE 7: e43759, 2012.
30. Zoccali C, Leonardis D, Enia G, Postorino M, Mallamaci F; MAURO study working group: The MAURO study: Multiple intervention and audit in renal diseases to optimize care. J Nephrol 21: 20–22, 2008.
31. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254, 2006.
32. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988.
33. Newcombe RG: Confidence Intervals for Proportion and Related Measures of Effect Size. Boca Raton, FL: CRC Press, 2013, pp 181–182.
34. Jager KJ, Zoccali C, Macleod A, Dekker FW: Confounding: What it is and how to deal with it. Kidney Int 73: 256–260, 2008.
35. Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C: Evaluating health outcomes in the presence of competing risks: A reviewof statistical methods and clinical applications. Med Care 48[Suppl]: S96–S105, 2010.
36. Steverberg EW: Clinical Prediction Models. A Practical Approach to Development,Validation, and Updating, New York, Springer, 2009. pp. 93–98 and 303–304.
37. Naka T, Nishimoto N, Kishimoto T: The paradigmof IL-6: Frombasic science to medicine. Arthritis Res 4[Suppl 3]: S233–S242, 2002.
38. Hartman J, Frishman WH: Inflammation and atherosclerosis: A review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 22: 147–151, 2014.
39. Baumann H, Gauldie J: Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 7: 147–159, 1990.
40. Morimoto S, Nabata T, Koh E, Shiraishi T, Fukuo K, Imanaka S, Kitano S, Miyashita Y, Ogihara T: Interleukin-6 stimulates proliferation of cultured vascular smooth muscle cells independently of interleukin-1 beta. J Cardiovasc Pharmacol 17 [Suppl 2]: S117–S118, 1991.
41. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6: 315–325, 1997.
42. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJ, Trautwein C, Luchtefeld M, Schmittkamp C, Heeneman S, Daemen MJ, Drexler H: Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110: 3493–3500, 2004.
43. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for in- flammation and plaque instability. Circulation 101: 1372–1378, 2000.
44. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB: Cardiovascular disease, interleukin-6, and risk of mortality in older women: TheWomen’s Health and Aging Study. Circulation 103: 947–953, 2001.
45. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100: 793–798, 1999.
46. Ikeda U, Ito T, Shimada K: Interleukin-6 and acute coronary syndrome. Clin Cardiol 24: 701–704, 2001.
47. Wang J, Shete S: A test for genetic association that incorporates information about deviation from Hardy-Weinberg proportions in cases. Am J Hum Genet 83: 53–63, 2008.
48. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjærg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AA, Trip MD, Steri M, Witteman JC, Qi L, van der Schoot CE, de Faire U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundström J, Wassertheil-Smoller S, Mellström D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, Davey-Smith G, de Bakker PI, O’Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson JO, Ohlsson C, Tivesten A°, Ljunggren O¨, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs FW, Kastelein JJ, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall AH, Ridker PM, Hólm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O, Danesh J; IL6R Genetics Consortium Emerging Risk Factors Collaboration: Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies. Lancet 379: 1205–1213, 2012.
49. Navarro G, Taroumian S, Barroso N, Duan L, Furst D: Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum 43: 458–469, 2014.